DOTATATE PET-CT for Cushing's Syndrome
Study Summary
This trial is testing whether a certain imaging technique can help doctors better locate the source of a hormone that is produced in excess in people with Cushing syndrome, and whether a medication can improve the accuracy of the imaging.
- Cushing's Syndrome
- Adrenocorticotropic Hormone
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Is there an age restriction for inclusion in this research?
"This medical study is accepting participants aged 18 to 80. There are 373 studies dedicated to underage individuals and 986 for those over 65 years of age."
Are there still available slots for interested enrollees in this research?
"As seen on clinicaltrials.gov, this study is actively seeking participants and was initially written up on February 12th 2014 with the last edit taking place September 7th 2022."
Has the FDA greenlighted DOTATATE PET-CT for general use?
"Our assessment at Power is that DOTATATE PET-CT has an approximate safety rating of 2. This evaluation takes into account the fact that this Phase 2 trial holds some evidence for safety, but lacks any substantive proof of efficacy."
For what volume of individuals is this clinical trial enrolling?
"Affirmative. The clinical trial database on ClinicalTrials.gov states that this research endeavour, posted initially in February of 2014 and edited as recently as September 2022, is actively searching for 80 participants from two distinct areas."
Would I qualify to partake in this research project?
"This medical trial is searching for 80 individuals with Cushing's Syndrome, ranging from 18 to 80 years old. Moreover, participants must be willing to return to the NIH for subsequent testing sessions."